I am a clinical epidemiologist with extensive expertise in infectious diseases and clinical trials, particularly in vaccine research for outbreak-prone infectious diseases. My PhD focused on assessing the safety and immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola virus disease (EVD) in Sierra Leone, providing critical insights into the complexities of vaccine research for emerging infections. As the responsible physician for the London School of Hygiene & Tropical Medicine (LSHTM), I led the safety working group of a large-scale Ebola vaccine trial in the Democratic Republic of Congo (DRC) that recruited over 20,000 adults and children, including 1,221 pregnant women, during the 2018-2020 EVD outbreak in North Kivu and Ituri provinces. I also coordinated a follow-up study on participants vaccinated with the same regimen (NCT03820739) and, as co-principal investigator at LSHTM, led a safety follow-up study in Tanzania, securing €145,967 in funding (NCT02661464).

My current research interests centre on improving the inclusion of pregnant and breastfeeding women in vaccine research for emerging infections, aiming to enhance maternal and neonatal safety during health emergencies. I am also dedicated to investigating the burden of Lassa fever and other emerging infections in pregnancy to inform vaccine development and deployment strategies. Beyond this, I am actively involved in projects exploring Lassa fever epidemiology in Sierra Leone and innovative delivery strategies for Human Papilloma Virus (HPV) vaccination.